奥美沙坦对原发性高血压患者血管内皮功能及高敏C反应蛋白的影响被引量：1

下载PDF

导出

摘要目的探讨奥美沙坦对原发性高血压患者血管内皮功能和高敏C反应蛋白的影响。方法选择40例原发性高血压患者,给予奥美沙坦20mg.d-1,共8周。观察治疗前后血浆内皮素-1(ET-1)、一氧化氮(NO)和高敏C反应蛋白(hs-CRP)的变化。另选40例健康正常体检者作为正常对照组。结果患者治疗前与对照组比较,血浆ET-1和hs-CRP明显升高,血浆NO明显降低(P<0.01);经奥美沙坦治疗8周后血浆ET-1和hs-CRP明显下降,血浆NO明显升高(P<0.01或P<0.05)。结论奥美沙坦能改善原发性高血压患者的血管内皮功能,具有抗炎作用。

作者朱群

机构地区浙江省桐庐县第三人民医院内科

出处《海峡药学》 2009年第3期106-108,共3页 Strait Pharmaceutical Journal

关键词奥美沙坦原发性高血压血管内皮功能高敏C反应蛋白

分类号 R969 [医药卫生—药理学]

引文网络
相关文献

参考文献12

1Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healtheare professionals from the Centers for Disease Control and Prevention and the American Heart Association [J]. Circulation, 2003, 107 (3) :499-511.
2吴进寿,洪华山.高血压与炎症关系的研究进展[J].中国临床药理学与治疗学,2006,11(2):136-140. 被引量：47
3诸骏仁,蔡迺绳,范维琥,朱鼎良,何奔,吴宗贵,柯元南,郭静萱,马虹,黄峻,李新立,陈运贞.奥美沙坦治疗轻、中度原发性高血压病人的疗效与安全性总结[J].中国新药与临床杂志,2006,25(3):236-237. 被引量：16
4Puddu P, Puddu GM, Zaca F, et al. Endothelial dysfunction in hypertention [J] . Acta Cardiol, 2000, 55 (4) : 221-232.
5Luscher TF, Noll G. Function as an end-point in interventional trials, concepts, methods and current date [J] .J Hypertens Suppl, 1996, 14 (2):111.
6Diaz JJ, Arguelles J, Malaga I, et al.C-reaetive protein is elevated in the offspring of parents with essential hypertension [J] .Arch Dis Child. 2007, 92(4) : 304-308.
7Bautista LE, Lopez J P, Vera LM, et al. ls c-reative protein an independent risk factor for essential hypertension? [J] .J Hypertens, 2001, 19(5) :857-861.
8Vallance P, Collier J, Bhagat K. Infection inflammation and infection: does acute endothelim dysfunction proceed a link [J]. Lancet, 1997, 349:1391-1392.
9Hayaishi-Okano R, Yamasaki Y, Katakami N, et al. Elevated C-reactive protein associates witl, early-stage carotid atherosclerosis in young subjects with typel diabetes[J] .Diabetes Care, 2002, 25 (8) : 1432-1438.
10Fichtlscherer S, Rosenberer G, Disk H, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease [J ] . Circulation, 2000, 102 ( 9 ) : 1000-1006.

二级参考文献42

1Badr K,Wainwright CL.Inflammation in the cardiovascular system:here,there and everywhere[J].Curr Opin Pharmacol,2004;4:107-9
2Ridker PM,Buring JE,Shih J,Matias M,Hennekens CH.Prospectivestudy of C-reactive protein and the risk of future cardiovascular eventsamong apparently healthy women[J].Circulation,1998;98:731-3
3Pradhan AD,Manson JE,Rifai N,Buring JE,Ridker PM.C-reactiveprotein,IL 6,and risk of developing type 2 diabetes mellitus[J].JAMA Assoc,2001;286:327-34
4Laaksonen DE,Niskanen L,Nyyssonen K,Punnonen K,Tuomainen TP,Valkonen VP,et al.C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men[J].Diabetologia,2004;47:1403-10
5Panza JA,Quyyumi AA,Brush JE,Epstein SE.Abnormal endothelium dependent vascular relaxation in patients with essential hypertension[J].N Engl J Med,1990; 323:22-7
6Linder L,Kiowski W,Buhler FR,Luscher TF.Direct evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo.Blunted responses in essential hypertension[J].Circulation,1990; 81:1762-7
7Brush JE Jr,Faxon DP,Salmon S,Jacobs AK,Ryan TJ.Abnormal edothelium-dependent coronary vasomotion in hypertensive patients[J].J Am Coll Cardiol,1992; 19:809-15
8Lo pez-Jaramillo P.Calcium,nitric oxide,and preeclampsia[J].Seminars Perinatol,2000; 24:33-6
9Schmid-Schonbein GW,Seiffge D,Delano FA,et al.Leukocyte counts and activation in spontaneously hypertensive and normotensive rats[J].Hypertension,1991;17:323-30
10McCarron RM,Wang L,Siren AL,Spatz M,Hallenbeck JM.Monocyte adhesion to cerebromicrovascular endothelial cells derived from hypertensive and normotensive rats[J].Am J Physiol,1994;267:H2491-7